搜索到 1000 条关于 오늘경마 Va222.top 일본 경마 중계 일본경마 오늘 경마 시작 시간 Azi 的文章

带心灵去旅行「精神食粮」送不停

2016.10.01 带心灵去旅行「精神食粮」送不停

推荐书」的 TOP.5 榜单吧!这是根据「医生阅读行为」调研活动中的 2102 份有效问卷得出的榜单,有很多医生推荐同行看这些书。看了医生推荐的 Top
与去年相比  全球在研新药呈现哪些变化?

2016.07.28 与去年相比 全球在研新药呈现哪些变化?

、生物技术类药物、神经系统药物、抗感染药物和复方药物为排名居 TOP 5 的治疗领域。其中,癌症仍是药品研发的核心领域,抗癌/抗肿瘤药物数量呈现显著增长态势,数量...,与 2015 年数据进行对比,可反映不同治疗类别在研药物数量的变化情况。从治疗类别 TOP 25 排名中发现,一般抗癌药 (在研药物 2071 个)、免疫类

2012.09.19 2011年生物仿制药会议(Biosimilars Asia 2011)

时间: 2011-5-23 至 2011-5-26
地点:Grand Hyatt Shanghai
主办单位: IBC Asia (S) Pte Ltd

会议简介

According to Business Insights, an estimated $25bn worth of biologics will lose patent protection by 2016, creating a significant market opportunity for biosimilars. However, the reality is that biosimilar development is a risk-fraught activity that demands significant resources in R&D, manufacturing expertise, regulatory know-how, clinical-trial capabilities, and a high level of financial investment.

Biosimilar development is riddled with complexities, ranging from regulatory, to manufacturing to marketing, and is one of the most expensive propositions in the pharmaceutical industry. It is estimated that it costs between US$100-200 million to bring a biosimilar product to market. With so much at stake, biosimilars represent not only substantial growth but equally risk..

IBC’s 2nd Annual Biosimilars Asia 2011 Summit is the ONLY conference in Asia catering to this region’s specific queries. With unprecedented insights from leading innovators and biosimilar companies, you will network and learn how to strategically position your company to maximize your ROI. Biosimilars Asia 2011 is attended by key stakeholders in the region and beyond, enabling you to make informed strategic decisions.

5 Reasons To Attend
  • Only conference in Asia which addresses concerns faced by the Asian biosimilar companies with experts from the region and beyond
  • Learn from and personally meet senior executives from the major stakeholders amongst from biosimilar to innovator companies
  • The most comprehensive event highlighting key challenges in the industry including manufacturing, marketing, pricing, transitioning from generics to biosimilars and regulatory issues
  • Showcasing unique case studies from leading Asian and international biosimilar companies
  • Gather the latest insights from regional biosimilar companies and MNCs about their strategic decisions and how they are positioning themselves for success

Industry Gurus / Speakers
Biocon, Pfizer, Genentech, Roche, Teva, Hospira, Sandoz, Momenta, Intas, Dr Reddy’s, Shenzhen Main Luck Pharmaceuticals

Past Attendees Include
Vice President, ASTRAZENECA INNOVATION CENTER (China)
Senior Director, GENENTECH INC, (USA)
Managing Director, BECTON DICKINSON CO (BD BIOSCIENCES) (Singapore)
Managing Director, ASAHI GLASS CO LTD (Japan)
Deputy General Manager, SINOPHARM (China)
Head, Biotech Research, USV LTD (India)
General Manager, JCR PHARMACEUTICALS CO LTD (Japan)
Vice President, R&D/Business Development, MAIN LUCK PHARMACEUTICALS INC (China)
Senior Research Associate, HANWHA CHEMICAL (South Korea)
Vice President, BOEHRINGER INGELHEIM GMBH (Germany)
General Manager, GLAXOSMITHKLINE (CHINA) INVESTMENT CO LTD (China)
IP Director, HOSPIRA (AUSTRALIA)
President, MYCENAX BIOTECH INC (Taiwan)
Senior Director, MERCK & CO INC (USA)
Associate Director, DR REDDY''''''''S LABORATORIES LTD (India)
Chairman, SHENZHEN SCIPROGEN BIO-PHARMACEUTICAL CO LTD (SCIPROGEN) (China)COO, SHANGHAI CELGEN BIOPHARMACEUTICALS (China)
Chief Representative, TTY BIOPHARM CO LTD (Taiwan)COO, 3SBIO (China)
Project Director, JIANGSU CHIA TAI TIANQING PHARMACEUTICAL CO LTD (China)Associate Director, PFIZER INVESTMENT CO LTD (China)
General Manager, NIPPON KAYAKU CO LTD (Japan)
President, HENLIUS BIOPHARMACEUTICALS INC & SHANGHAI HENLIUS BIOTECH (USA)
Vice President, RANBAXY (USA)

Registration

FEES per delegate
Early Bird Rate
Register & Pay before 11 March 2011
Special Rate
Register & Pay before 15 April 2011
Normal Rate
Register & Pay after 15 April 2011
Group Rate
Group of 3 or more
?
US$ / CNY
US$ / CNY
US$ / CNY
US$ / CNY
4 day package
(Conf + Pre & Post Workshops)
2,495 /
16,600
2,695 /
17,950
2,895 /
19,500
2,175 /
14,650
3.5 day package (Conf + Workshop C & A or B )

2,295 /
15,500

2,495 /
16,600
2,695 /
17,950
2,025 /
13,500
3 day package (Conf + Workshop A & B or C)
1,995 /
13,500
2,195 /
14,600
2,395 /
15,950

1,795 /
12,000

2.5 day package (Conf + Workshop A or B)
1,795 /
12,000
1,995 /
13,500
2,195 /
14,600
1,695 /
10,950
2 day package
(Conf only)
1,495 /
9,950
1,695 /
11,300
1,895 /
12,600
1,495 /
9,950

Register Now

PAYMENT TERMS

Payment must be received 10 business days prior to the event. To take advantage of discounts with an expiry cut-off date, registration and payment must be received by the cut off date.

Payments by Singapore Dollars (S$)

  • Payments by S$ bank draft or cheque should be made in favour of “IBC Asia (S) Pte Ltd” payable in Singapore.
  • Payment by telegraphic transfer in S$ must be made to:
    IBC Asia (S) Pte Ltd
    A/C No.: 147-059513-001 (SGD)
    The Hongkong and Shanghai Banking Corporation Limited
    21 Collyer Quay, HSBC Building, Singapore 049320
    Bank Swift Code: HSBCSGSG
    Bank Code: 7232
  • Payment by Credit Card (AMEX, VISA or MASTERCARD). Please provide your Card Number, Name of Cardholder, Expiry Date and your Signature and send it by fax to +65 6508 2407.
Payments by RMB (CNY)
  • Payment by telegraphic transfer in CNY must be made to:
    A/C Name:
    A/C No.: 720-031103-001
    Beneficiary Bank:
    Bank Address: No. 1000 Lujiazui Rind Road,
    Pudong, Shanghai 200120, P.R. China
    Bank Swift Code: HSBCCNSH
CANCELLATIONS SUBSTITUTION
Should you be unable to attend, a substitute delegate is welcome at no extra charge. Cancellations must be received in writing at least 10 business days before the start of the event, to receive a refund less 10% processing fee per registration. The company regrets that no refund will be made available for cancellation notifications received less than 10 business days before the event.IMPORTANT NOTE:
Please quote the name of the delegate, event title and invoice number on the advice when remitting payment. Bank charges are to be deducted from participating organisations own accounts. Please fax your payment details (copy of remittance advice, cheque or draft to +65 6508 2407.

Attendance will only be permitted upon receipt of full payment. Participants wishing to register at the door are responsible to ensure all details are as published. IBC Asia will not be responsible for any event re-scheduled or cancelled.


DATA PROTECTION
The personal information entered during your registration/order, or provided by you, will be held on a database and may be shared with companies in the Informa Group in the UK and internationally. Sometimes your details may be obtained from or shared with external companies for marketing purposes. If you do not wish your details to be used for this purpose, please contact Winnie Seah (Database) on winnie.seah@ibcasia.com.sg Tel: +65 6508 2468 or Fax: +65 6508 2408.
联系方式电话:+65 650 82401

2022.04.14 2021「中国高被引学者」单发布:清华浙大北大居高校前三

,其中6所大学的高被引学者数量超过了100位。清华大学共有222位,位居第一;浙江大学共有184位,位居第二;第三名为北京大学172位;第四、五名分别为上海

2019.03.18 2019年滴水湖第4届高峰论坛暨糖尿病慢性并发症的防治学科群管理模式国家级继续教育学习班

交通大学附属第六人民医院东院大礼堂(上海市浦东新区南汇新城镇环湖西三路222号)四、注册 费:0元/人 住宿费自理五、报名日期:2019年3月15--4月11日六
NASS2016:颈椎开门手术中椎板切除患者再手术率较未切除者高

2016.10.31 NASS2016:颈椎开门手术中椎板切除患者再手术率较未切除者高

再手术率及相关因素进行了系统分析。作者回顾性分析了 2005 年 1 月至 2012 年 10 月 31 日 222 例接受椎板成型术的患者,系统研究了术后

2016.02.23 注册

。即刻报名>>联系我们● 北方区域:李女士 010-85679966-222● 南方区域:沈

2015.05.22 NEJM:AZD9291用于T790M耐药突变的NSCLC疗效显著

的、先前EGFR-TKI治疗后疾病进展的晚期肺癌患者。剂量递增组31例、5个剂量扩增组222例,用药方案是每日一次20~240mg的AZD9291。研究终点
DAVF时软脑膜静脉回流直接与出血水肿相关

2014.07.03 DAVF时软脑膜静脉回流直接与出血水肿相关

静脉回流相比,前者与出血水肿更直接相关,研究发表于最新一期的《Neurology》杂志中。研究者评估了222例DAVF患者PVR或者CVR的发生与出血
Varenicline联合安非他酮用于自适应戒烟安全有效

2014.06.28 Varenicline联合安非他酮用于自适应戒烟安全有效

Psychiatry上。该随机、双盲、平行组自适应治疗试验共纳入222名使用尼古丁贴片治疗1周后,吸烟量降低小于50%的吸烟者。随机给予吸烟者
强化血糖控制可降低手术部位感染发生率

2014.04.05 强化血糖控制可降低手术部位感染发生率

目标范围为7.7-10.0mmol/l)。研究主要终点为手术部位感染发生率。研究结果中,分别有225例患者和222例患者被分到普通胰岛素治疗组和强化
Gaenslen’s实验阳性的RA患者疾病活动度高

2013.05.25 Gaenslen’s实验阳性的RA患者疾病活动度高

设置了GT阴性组(n=222)。两组在性别、年龄、病程、类风湿因子(RF)阳性等方面相匹配。研究者对疾病活动积分、肿胀关节数和疼痛关节数、患者自我整体评估、医生

2013.03.21 交通指南

;>武昌火车站乘222路或61路至鹦鹉大道铜锣湾广场转乘554路在武汉国际博览中心(北)站下车步行至武汉国际博览中心。>>>
2021 年 6 月最受欢迎的品牌案例

2021.08.02 2021 年 6 月最受欢迎的品牌案例

本期「TOP list ·月度案例评选」是基于 6 月在丁香园医院汇平台上发布的文章,根据阅读量及点赞量呈现医疗行业「最受欢迎的品牌案例」TOP 10。医院汇努力为医疗行业从业者打造优秀品牌案例库,供行业宣传人士参考学习,也是众医院打造品牌曝光的重要营地。新闻资讯 TOP 10排名医院
2020 年 6 月最受欢迎的品牌案例

2020.06.30 2020 年 6 月最受欢迎的品牌案例

本期「TOP list ·月度案例评选」是基于 6 月在丁香园 医院汇 平台上发布的文章,根据阅读量及点赞量呈现医疗行业「最受欢迎的品牌案例」TOP 10。医院汇努力为医疗行业从业者打造优秀品牌案例库,供行业宣传人士参考学习,也是众医院打造品牌曝光的重要营地。新闻资讯 TOP 10
丁香园力荐 最受医生欢迎的 20 本必备好书

2015.11.14 丁香园力荐 最受医生欢迎的 20 本必备好书

「借花献佛」,和大家分享下推荐最多的 10 本 「案头必备」和 10 本 「床头必备」好书。一、案头必备TOP 1. 实用内科学推荐理由:中国医学界唯一一部畅销...出版一次,已出至第14版,可及时反映国内外进展,是内科领域各级学科医师的 「不二宝典」。TOP 2. 坎贝尔骨科手术学推荐理由:国际权威骨科经典著作,内含众多
2013年5大重磅新药

2013.12.27 2013年5大重磅新药

2013年岁末已至,回首这一年,一批「重磅炸弹」级新药的诞生,使得生物制药成为全球医药领域的一个焦点。Top1 默克...晚期黑色素瘤临床试验和非小细胞肺癌试验结果提交给监管机构。Top2 糖尿病治疗的新突破强生和Evotec公司共同开发
上一页 1 2 3 ... 33 34 35 ... 48 49 50 下一页 到第